A systematic review of the incidence and prevalence of long-term neurological conditions in the UK

Neuroepidemiology

Volumn 36, Issue 1, 2011, Pages 19-28

  Hoppitt, Thomas ^a   Pall, Hardev ^a   Calvert, Mel ^b   Gill, Paramjit ^b   Yao, Guiqing ^b   Ramsay, Jill ^b   James, Gill ^b   Conduit, Jacky ^b   Sackley, Cath ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

Charcot Marie tooth disease; Dominantly inherited ataxias; Huntington's disease; Motor neurone disease; Multiple system atrophy; Postpolio syndrome; Progressive supranuclear palsy

Indexed keywords

CHRONIC DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUNTINGTON CHOREA; INCIDENCE; MOTOR NEURON DISEASE; PREVALENCE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM;

AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; CHARCOT-MARIE-TOOTH DISEASE; GREAT BRITAIN; HUMANS; HUNTINGTON DISEASE; INCIDENCE; MULTIPLE SYSTEM ATROPHY; POSTPOLIOMYELITIS SYNDROME; PREVALENCE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 78349247202     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321712     Document Type: Review

References (34)

1. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, Clarke J, Sakel M, Ampong M-A, Shaw CE, Leigh PN, Al-Chalabi A: Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England Register for Amyotrophic Lateral Sclerosis (SEALS Registry). Neuroepidemiology 2007; 29: 44-48.
2. Forbes RB, Colville S, Parratt J, Swingler RJ: The incidence of motor neuron disease in Scotland. J Neurol 2007; 254: 866-869.
3. Johnson C, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, Ampong MA, Shaw CE, Leigh PN, Al-Chalabi A: Amyotrophic lateral sclerosis in an urban setting: a population- based study of inner city London. J Neurol 2006; 253: 1642-1643.
4. Mitchell JD, Gatrell AC, Al-Hamad A, Davies RB, Batterby G: Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria. J Neurol Neurosurg Psychiatry 1998; 65: 842-847.
5. James CM, Harper PS, Wiles CM: Motor neurone disease: a study of prevalence and disability. QJM 1994; 87: 693-699.
6. Morrison PJ, Johnston WP, Nevin NC: The epidemiology of Huntington's disease in Northern Ireland. J Med Genet 1995; 32: 524-530.
7. James CM, Houlihan GD, Snell RG, Cheadle JP, Harper PS: Late-onset Huntington's disease: a clinical and molecular study. Age Ageing 1994; 23: 445-448.
8. Watt DC, Seller A: A clinico-genetic study of psychiatric disorder in Huntington's chorea. Psychol Med 1993;(suppl 23):1-46.
9. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, Burn DJ: The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124(pt 7):1438-1449. (Pubitemid 32606104)
10. Craig K, Keers SM, Walls TJ, Curtis A, Chinnery PF: Minimum prevalence of spinocerebellar ataxia 17 in the north east of England. J Neurol Sci 2005; 239: 105-109.
11. Craig K, Keers SM, Archibald K, Curtis A, Chinnery PF: Molecular epidemiology of spinocerebellar ataxia type 6. Ann Neurol 2004; 55: 752-755.
12. Schrag A, Ben-Shlomo Y, Quinn NP: Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-1775.
13. Simpson SA, Johnston AW: The prevalence and patterns of care of Huntington's chorea in Grampian. Br J Psychiatry 1989; 155: 799-804.
14. Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, Shaw CE, Powell JF, Leigh PN: Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-164.
15. Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, Aoki M, Tsuji S, Yuasa T, Takano H, Hayashi H, Kuzuhara S, Sobue G, Research Committee on the Neurodegenerative Diseases of Japan: Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci 2009; 276: 163-169.
16. 2001 census. Office for National Statistics.
17. 2001 census for Scotland. General Register Office for Scotland.
18. Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B: The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721-728.
19. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y: Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol 1985; 232: 295-300.
20. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F, et al: The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-1322.
21. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL: The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993; 43: 751-755.
22. Haverkamp LJ, Appel V, Appel SH: Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-719.
23. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C: Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009; 3:CD006456.
24. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC: Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38: 1031-1034.
25. Chio A, Magnani C, Schiffer D: Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998; 13: 400-405.
26. Wermuth L, Joensen P, Bünger N, Jeune B: High prevalence of Parkinson's disease in the Faroe Islands. Neurology 1997; 49: 426-432.
27. Skre H: Genetic and clinical aspects of Charcot- Marie-Tooth's disease. Clin Genet 1974; 6: 98-118.
28. Vasconcelos OM, Prokhorenko OA, Salajegheh MK, Kelley KF, Livornese K, Olsen CH, Vo AH, Dalakas MC, Halstead LS, Jabbari B, Campbell WW: Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology 2007; 68: 1680-1686.
29. Chan KM, Amirjani N, Sumrain M, Clarke A, Strohschein FJ: Randomized controlled trial of strength training in post-polio patients. Muscle Nerve 2003; 27: 332-338.
30. On AY, Oncu J, Uludag B, Ertekin C: Effects of lamotrigine on the symptoms and life qualities of patients with post-polio syndrome: a randomized, controlled study. NeuroRehabilitation 2005; 20: 245-251.
31. Gonzalez H, Sunnerhagen KS, Sjöberg I, Kaponides G, Olsson T, Borg K: Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 2006; 5: 493-500.
32. Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA: Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 2007; 14: 60-65.
33. Skough K, Krossén C, Heiwe S, Theorell H, Borg K: Effects of resistance training in combination with coenzyme Q 10 supplementation in patients with post-polio: a pilot study. J Rehabil Med 2008; 40: 773-775.
34. Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical Limits of Amyotrophic Lateral Sclerosis' Workshop Contributors. J Neurol Sci 1994; 124(suppl):96-107.